Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
BCR-ABL1 tyrosine kinase
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "BCR-ABL1 tyrosine kinase" in MCE Product Catalog:
2
Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research . Vodobatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
1
Target:
Research Areas:
Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .
Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .
Cat. No.: HY-18819
CAS No.: 897369-18-5
BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1 native and ABL1 T315I, respectively.
Cat. No.: HY-179247
BCR-ABL1-IN-2 (compound 8) is a potent BCR-ABL1 tyrosine kinase inhibitor. BCR-ABL1-IN-2 exhibits activity in Imatinib (HY-15463) resistant K562/DOX cells with LC50 of 5.29 μM. BCR-ABL1-IN-2 shows no significant toxicity in nontumor cells. BCR-ABL1-IN-2 can be used for chronic myeloid leukemia research .
Cat. No.: HY-162489
Tyrosine kinase-IN-8 (compound 4e) is a BCR‐ABL1 tyrosine kinase inhibitor (TKI). Tyrosine kinase-IN-8 shows anti-proliferative activity against K562 cells, a chronic myeloid leukemia (CML) cell line (CC50=0.8 µM). Tyrosine kinase-IN-8 can be used in the study of chronic leukemia .
Cat. No.: HY-15728S
CAS No.: 2754051-83-5
Synonyms: IY-5511-d6
Cat. No.: HY-P706226
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABL1; BCR/ABL1 E1a2 Fusion Protein; Prev. ABL; BCR/C-ABL Oncogene Protein; JTK7; Chimeric BCR::ABL1 Protein; P150; BCR::ABL1 Fusion Protein; C-ABL; BCR/ABL E8a2 Fusion; V-ABL Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/ABL1 Fusion; C-ABL Oncogene 1, Receptor tyrosine kinase; BCR-ABL1 P190; Abelson tyrosine-Protein kinase 1; ABL1 Protein; tyrosine-Protein kinase ABL1; BCR-ABL; Proto-Oncogene C-ABL; BCR/ABL; Abelson Murine Leukemia Viral Oncogene Homolog 1; CHDSKM; ABL Protooncogene 1 Nonreceptor tyrosine kinase; C-ABL1; C-ABL Oncogene 1, Non-Receptor tyrosine kinase; V-ABL; Proto-Oncogene tyrosine-Protein kinase ABL1; C-ABL; ABL Proto-Oncogene 1, Non-Receptor tyrosine kinase; BCR/ABL1 Fusion Protein E3a1
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P706237
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: ABL1; BCR/ABL1 E1a2 Fusion Protein; Prev. ABL; BCR/C-ABL Oncogene Protein; JTK7; Chimeric BCR::ABL1 Protein; P150; BCR::ABL1 Fusion Protein; C-ABL; BCR/ABL E8a2 Fusion; V-ABL Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/ABL1 Fusion; C-ABL Oncogene 1, Receptor tyrosine kinase; BCR-ABL1 P190; Abelson tyrosine-Protein kinase 1; ABL1 Protein; tyrosine-Protein kinase ABL1; BCR-ABL; Proto-Oncogene C-ABL; BCR/ABL; Abelson Murine Leukemia Viral Oncogene Homolog 1; CHDSKM; ABL Protooncogene 1 Nonreceptor tyrosine kinase; C-ABL1; C-ABL Oncogene 1, Non-Receptor tyrosine kinase; V-ABL; Proto-Oncogene tyrosine-Protein kinase ABL1; C-ABL; ABL Proto-Oncogene 1, Non-Receptor tyrosine kinase; BCR/ABL1 Fusion Protein E3a1
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-182792
CAS No.: 2412966-86-8
Synonyms: TERN-701
Embibatinib (TERN-701) is an orally active and allosteric BCR-ABL1 tyrosine kinase inhibitor targeting the myristoyl pocket. Embibatinib exhibits an IC50 of 0.38 nM against ABL1 wild-type enzyme. Embibatinib can be used for the study of chronic myeloid leukemia (CML) .
Cat. No.: HY-185916
CAS No.: 2412969-11-8
BCR-ABL-IN-14 is a tyrosine kinase inhibitor targeting BCR-ABL1, ABL1 and ABL2. BCR-ABL-IN-14 inhibits chronic myeloid leukemia cells. It is applicable to research related to chronic myeloid leukemia, acute myeloid leukemia and acute lymphoblastic leukemia .
Cat. No.: HY-179460
CAS No.: 926037-85-6
Synonyms: IY-5511 dihydrochloride
Target:
Research Areas:
Radotinib (IY-5511) dihydrochloride is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib dihydrochloride has anti-prion and anti-tumor activities. Radotinib dihydrochloride can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib dihydrochloride can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .
Cat. No.: HY-103032R
CAS No.: 778274-97-8
Target:
Research Areas:
Multi-kinase inhibitor 1 (Standard) is the analytical standard of Multi-kinase inhibitor 1 (HY-103032). This product is intended for research and analytical applications. Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
